SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

OneSource Specialty Pharma informs about press release

10 Apr 2025 Evaluate

OneSource Specialty Pharma has informed that it enclosed a press release made by the Company with respect to Good Manufacturing Practices (GMP) certification by ANVISA, the Brazilian Health Regulatory Agency, for OneSource flagship Unit 2 facility, following a successful regulatory inspection from November 18, 2024 to November 22, 2024. The above information is also available on the website of the Company: https://www.onesourcecdmo.com/investorrelations/stock-exchange-intimation/.

The above information is a part of company’s filings submitted to BSE.

Onesource Specialty Share Price

1540.35 34.40 (2.28%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×